LYNPARZA (olaparib)

LynparzaTM (olaparib) is a first‐in‐class PARP inhibitor (PARPi) that allows women with BRCA mutated (BRCAm) platinum‐sensitive relapsed high-grade serous ovarian cancer to extend progression‐free survival (PFS).1-3

About Study 19

Quality of Life (QOL)

Quality of Life (QOL) was similar whether patients were on Lynparza or placebo.3,4

No statistically significant differences were observed between Lynparza and placebo in patient reported symptoms or health-related quality of life (HRQoL) as measured by improvement and worsening rates in the FACT/NCCN ovarian symptom index (FOSI), trial outcome index (TOI) and functional analysis of cancer therapy–ovarian total score (FACT-O total). 3,4

Quality of life was similar whether patients were on Lynparza or placebo.
Quality of life was similar whether patients were on Lynparza or placebo.

Safety and Tolerability

The safety and tolerability of Lynparza are acceptable for oral maintenance treatment administration.4

The most common adverse events associated with Lynparza monotherapy for patients identified with BRCAm were nausea, fatigue and vomiting and were generally mild to moderate (grade 1 or 2) in severity.4 The most common Grade 3 and 4 adverse events reported for Lynparza vs placebo were fatigue (7% vs 2%) and anaemia (5% vs 2%), neutropenia (4% vs 2%) and vomiting (3% vs 0%).3, 4

Adverse events
Adverse events